Screener
Edgewise Therapeutics, Inc. EWTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Exercise of stock options | 12,173 | 2,261 |
| Payment of deferred offering costs | — | (38) |
| Net cash provided by financing activities | 12,173 | 2,223 |
| Net change in cash and cash equivalents | (27,937) | 8,255 |
| Cash and cash equivalents at beginning of period | 61,148 | 41,666 |
| Cash and cash equivalents at end of period | $33,211 | $49,921 |
| Supplemental disclosures of non-cash investing and financing activities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s financing cash flow?
- Edgewise Therapeutics, Inc. (EWTX) reported financing cash flow of $12.17M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Edgewise Therapeutics, Inc.'s financing cash flow increased by 447.6% year-over-year, from $2.22M to $12.17M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s financing cash flow has grown at a 1.2% compound annual growth rate (CAGR), from $187.28M to $196.09M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Edgewise Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude